Meeting
2016 ASCO Annual Meeting
Burden of febrile neutropenia hospitalizations (FNH) in U.S. clinical practice, by use and patterns of colony-stimulating factor prophylaxis (CP).
Authors
Derek Weycker
Policy Analysis Inc. (PAI), Brookline, MA
Derek Weycker , Xiaoyan Li , Spiros Tzivelekis , Mark Atwood , Jacob Garcia , Yanli Li , Maureen Reiner , Gary H. Lyman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6568)
DOI
10.1200/JCO.2016.34.15_suppl.6568
Abstract #
6568
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2015 ASCO Annual Meeting
Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.
First Author: Lindsey Martin Goodman
Poster
2014 ASCO Annual Meeting
Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).
First Author: Ines Maria Vaz Duarte Luis
Poster
2023 ASCO Genitourinary Cancers Symposium
A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.
First Author: Nely Mercy Diaz Mejia